Romel Somwar

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 24 papers. Top paper: “NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors”.

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications Biology(2020)10.1038/s42003-020-01508-w

N/A

2.2DataRank · unranked

63 citations

Nicolle E. Hofmann, Bryan D. Smith, Igor Odintsov, Morana Vojnic, Irina Linkov +10 more

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3321

N/A

0DataRank · unranked

48 citations

Adam J. Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa +17 more

Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.09.019

N/A

0DataRank · unranked

19 citations

Michael Offin, Daisuke Kubota, Helena A. Yu, Clare Wilhelm, Shinichi Toyooka +4 more

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Disease Models & Mechanisms(2020)10.1242/dmm.047779

N/A

0DataRank · unranked

12 citations

Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos +17 more

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3605

N/A

0DataRank · unranked

51 citations

Allan J.W. Lui, Whitney J. Sisso, Eric Gladstone, Zebing Liu, Lukas Delasos +10 more

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

Disease Models & Mechanisms(2021)10.1242/dmm.047621

N/A

0DataRank · unranked

33 citations

Igor Odintsov, Zebing Liu, Allan J.W. Lui, Takuo Hayashi, Morana Vojnic +22 more

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.03.013

N/A

0DataRank · unranked

32 citations

Marissa S. Mattar, Allan J.W. Lui, Michael Offin, Christopher Kurzatkowski, Lukas Delasos +9 more

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1119

N/A

0DataRank · unranked

168 citations

Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar +17 more

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Oncogene(2022)10.1038/s41388-022-02305-x

N/A

0DataRank · unranked

41 citations

Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang +10 more

Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells

Cell Reports(2022)10.1016/j.celrep.2022.110343

N/A

0DataRank · unranked

30 citations

John R. Ferrarone, Alvin Liu, Christina Brandstädter, Ravi S. N. Munuganti, Dylan Farnsworth +21 more

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1 -Fusion-Positive Lung Cancer

Molecular Cancer Research(2022)10.1158/1541-7786.mcr-22-0025

N/A

0DataRank · unranked

11 citations

Igor Odintsov, Adam J. Schoenfeld, Evan Siau, Marissa S. Mattar, Elisa de Stanchina +7 more

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Cancer Research(2022)10.1158/0008-5472.can-21-1397

N/A

0DataRank · unranked

6 citations

Michael V. Ortiz, Inna Khodos, Marissa S. Mattar, Allan J.W. Lui, Shinji Kohsaka +5 more

Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2024

N/A

0DataRank · unranked

8 citations

Allan J.W. Lui, Kota Ishizawa, Isao Miyazaki, Inna Khodos, Kentaro Wakayama +11 more

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Nature Cancer(2023)10.1038/s43018-023-00630-y

N/A

0DataRank · unranked

38 citations

Igor Odintsov, Keiji Ishida, Allan J.W. Lui, Masanori Kato, Tatsuya Suzuki +28 more

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.12.019

N/A

0DataRank · unranked

24 citations

Maisam Makarem, Mizuki Nishino, S. Emily Bachert, Tom Zhang, Jaclyn LoPiccolo +11 more

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.05.007

N/A

0DataRank · unranked

20 citations

Igor Odintsov, Vladimir Markov, Rebecca Caeser, Paweł Sobczuk, Sam E. Tischfield +14 more

Data from CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

(2023)10.1158/0008-5472.c.6513894.v1

N/A

0DataRank · unranked

0 citations

Michael V. Ortiz, Inna Khodos, Marissa S. Mattar, Allan J.W. Lui, Shinji Kohsaka +5 more

Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy

Cancer Discovery(2024)10.1158/2159-8290.cd-23-0110

N/A

0DataRank · unranked

45 citations

Daniel Cameron, Helen S. Mueller, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti +11 more

HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1835

N/A

0DataRank · unranked

19 citations

Christopher A. Febres‐Aldana, Zebing Liu, Jenna-Marie Dix, Ryan Cheng, Raymond G. Dematteo +13 more

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3981

N/A

0DataRank · unranked

12 citations

Soo‐Ryum Yang, Jessica J. Tao, Antoine Desîlets, Eli L. Diamond, Clare Wilhelm +18 more

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Journal of Clinical Investigation(2025)10.1172/jci179282

N/A

0DataRank · unranked

5 citations

Helen S. Mueller, Daniel Cameron, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti +12 more

Clinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma

npj Precision Oncology(2025)10.1038/s41698-025-01076-4

N/A

0DataRank · unranked

2 citations

Christopher A. Febres‐Aldana, Juan Luis Gomez Marti, Saeed Asiry, Tamika Wong, John A. Boockvar +5 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278

N/A

0DataRank · unranked

124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.09.19.677259

N/A

0DataRank · unranked

0 citations

Tom Zhang, Ryan R. Cheng, Marissa S. Mattar, Juan Luis Gomez Marti, Leo Gili +12 more